By Mariam Sunny (Reuters) -Biohaven said on Monday its experimental treatment for a rare neuromuscular disorder failed to significantly improve motor function in a late-stage trial, sending the shares ...

Despite disappointing results in the genetic neurodegenerative disorder, the drug shows potential for treating obesity.

The New Haven, Conn., biopharmaceutical company said Monday that taldefgrobep had shown clinically meaningful improvements in motor function in spinal muscular atrophy patients, but the treatment arm ...

Biohaven said on Monday its experimental treatment for spinal muscular atrophy helped improve patients' motor function in a late-stage study, but failed to achieve statistical significance compared to ...

A phase 3 trial of Biohaven’s taldefgrobep alfa in spinal muscular atrophy (SMA) has missed its primary endpoint. The biotech ...

The setback likely removes one competitor to an emerging spinal muscular atrophy medicine from Scholar Rock, but sets the ...

While taldefgrobep alfa failed to show improved motor function in spinal muscular atrophy, treated patients saw a marked ...

OVER 2,000 people participated in a charity fun run themed “Together We Care” aimed at raising awareness and support for individuals affected by spinal muscular atrophy (SMA).

The three accused allegedly misused money collected for the treatment of a four-month-old child in the name of Spinal Muscular Atrophy, SMA-1.

Karnataka launched free treatment for Spinal Muscular Atrophy (SMA) at the Indira Gandhi Institute of Child Health in ...

The appeal was made in the name of actress Sana Khan, who was unaware that her was being used. They said the treatment would cost Rs 17 crores was defrauded of Rs 4.5 crore by posting a video on ...